Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles.

IF 4 Q1 CLINICAL NEUROLOGY
Yury Loika, Stephanie Webster, Elena Loiko, Alexander M Kulminski
{"title":"Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and <i>APOE</i> alleles.","authors":"Yury Loika, Stephanie Webster, Elena Loiko, Alexander M Kulminski","doi":"10.1002/dad2.70016","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Neurofibrillary tangles (NFTs), a hallmark of tau pathology in Alzheimer's disease (AD), accumulate in the aging brain. However, some individuals remain cognitively intact despite high Braak (III-VI) stages, which characterize NFTs' accumulation.</p><p><strong>Methods: </strong>We studied resistance and resilience to tau pathology by assessing Braak stages based on apolipoprotein E (<i>APOE</i>) alleles, sex, and age in a sample of 1932 cognitively intact individuals of European ancestry from the Alzheimer's Disease Sequencing Project (ADSP).</p><p><strong>Results: </strong>Resistance, characterized by low (0-II) Braak stages, was observed in men and women younger than 85 years of age. Resilience, indicated by high (III-VI) Braak stages, increased significantly with age in both men and women for each <i>APOE</i> allele. It became more pronounced, with the proportion of high Braak stages exceeding 50% at 85 years and older in women, irrespective of the <i>APOE</i> allele.</p><p><strong>Discussion: </strong>The identification of factors underlying resistance and resilience against AD-related pathologies is essential for promoting cognitively healthy aging.</p><p><strong>Highlights: </strong>We investigated cognitive resistance and resilience to tau pathology in Alzheimer's disease (AD).This study included individuals who were not diagnosed with AD.Braak stages 0-II and III-VI were considered as a measure of resistance and resilience, respectively.Resistance was stronger at ages younger than 85 years in non-carriers of the apolipoprotein E (<i>APOE</i>) ε4 allele.Resilience increased with age for each <i>APOE</i> allele independently of sex.At age 85 years and older, high resilience (>50%) was observed in women regardless of the <i>APOE</i> allele.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 4","pages":"e70016"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470232/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Neurofibrillary tangles (NFTs), a hallmark of tau pathology in Alzheimer's disease (AD), accumulate in the aging brain. However, some individuals remain cognitively intact despite high Braak (III-VI) stages, which characterize NFTs' accumulation.

Methods: We studied resistance and resilience to tau pathology by assessing Braak stages based on apolipoprotein E (APOE) alleles, sex, and age in a sample of 1932 cognitively intact individuals of European ancestry from the Alzheimer's Disease Sequencing Project (ADSP).

Results: Resistance, characterized by low (0-II) Braak stages, was observed in men and women younger than 85 years of age. Resilience, indicated by high (III-VI) Braak stages, increased significantly with age in both men and women for each APOE allele. It became more pronounced, with the proportion of high Braak stages exceeding 50% at 85 years and older in women, irrespective of the APOE allele.

Discussion: The identification of factors underlying resistance and resilience against AD-related pathologies is essential for promoting cognitively healthy aging.

Highlights: We investigated cognitive resistance and resilience to tau pathology in Alzheimer's disease (AD).This study included individuals who were not diagnosed with AD.Braak stages 0-II and III-VI were considered as a measure of resistance and resilience, respectively.Resistance was stronger at ages younger than 85 years in non-carriers of the apolipoprotein E (APOE) ε4 allele.Resilience increased with age for each APOE allele independently of sex.At age 85 years and older, high resilience (>50%) was observed in women regardless of the APOE allele.

阿尔茨海默氏症患者对 tau 病理学的抵抗力和恢复力:年龄、性别和 APOE 等位基因的影响
导言:神经纤维缠结(NFTs)是阿尔茨海默病(AD)中tau病理学的标志,会在衰老的大脑中积累。然而,一些人尽管处于NFT堆积的高Braak(III-VI)阶段,但认知能力仍然完好无损:我们根据脂蛋白E(APOE)等位基因、性别和年龄评估了阿尔茨海默病测序项目(ADSP)中1932名认知功能完好的欧洲血统个体的Braak阶段,从而研究了他们对tau病理学的抵抗力和恢复力:在 85 岁以下的男性和女性中观察到了以低(0-II)布拉克分期为特征的抵抗力。抗逆性表现为布拉克分期较高(III-VI),随着年龄的增长,每个 APOE 等位基因的男性和女性抗逆性均显著增加。在 85 岁及以上的女性中,无论 APOE 等位基因如何,高布拉克分期的比例都超过了 50%:讨论:确定抗击和抵御注意力缺失症相关病症的潜在因素对于促进认知健康老龄化至关重要:我们调查了阿尔茨海默病(AD)患者对tau病理学的认知抵抗力和恢复力。该研究纳入了未确诊为AD的患者。Braak分期0-II期和III-VI期分别被视为抵抗力和恢复力的衡量标准。在年龄小于85岁的非载脂蛋白E(APOE)ε4等位基因携带者中,抵抗力更强。在85岁及以上年龄段,无论APOE等位基因如何,女性的抵抗力都很强(>50%)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
7.50%
发文量
101
审稿时长
8 weeks
期刊介绍: Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信